A TARGETED PHASE I/II TRIAL OF ZD6474 (VANDETANIB; ZACTIMA) PLUS THE PROTEASOME INHIBITOR, BORTEZOMIB (VELCADE ), IN ADULTS WITH SOLID TUMORS WITH A FOCUS ON HEREDITARY OR SPORADIC, LOCALLY ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC):